Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing live Shigella vaccines using lambda Red recombineering.

Ryan T Ranallo1, Shoshana Barnoy, Sejal Thakkar

  • 1Department of Enteric Infections, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. ryan.ranallo@na.amedd.army.mil

FEMS Immunology and Medical Microbiology
|July 29, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial.

The Lancet. Infectious diseases·2026
Same author

National Institutes of Health-Wide Workshop: Impact of Diet on Mucosal Immunity and Immune-Mediated Inflammatory Diseases of the Gastrointestinal Tract.

Gastro hep advances·2025
Same author

Neuroimmune interactions in health and disease.

Nature immunology·2025
Same author

BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.

Vaccine·2025
Same author

A rhesus macaque intragastric challenge model for evaluating the safety, immunogenicity, and efficacy of live-attenuated <i>Shigella dysenteriae</i> 1 vaccine candidates.

Frontiers in microbiology·2024
Same author

BECC-engineered live-attenuated <i>Shigella</i> vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.

Research square·2024

Live attenuated Shigella vaccines show promise. Advanced recombineering techniques enable precise genetic engineering of Shigella for improved vaccine development, creating safer and more effective Shigella vaccine strains.

Area of Science:

  • Microbiology
  • Vaccinology
  • Bacterial Genetics

Background:

  • Live attenuated Shigella vaccines demonstrate potential for protective immunity and antigen delivery.
  • Traditional genetic engineering methods for Shigella vaccine development are complex and time-consuming.
  • Recombineering offers a more efficient alternative for bacterial genome modification.

Purpose of the Study:

  • To explore the application of advanced recombineering techniques for Shigella vaccine strain development.
  • To create and characterize isogenic Shigella strains with deletions in virulence-associated genes.
  • To generate prototypic Shigella vaccine candidates using recombineering.

Main Methods:

  • Utilized lambda red recombineering for targeted genomic DNA modification in Shigella.

Related Experiment Videos

  • Engineered linear antibiotic resistance cassettes with homologous sequences for integration.
  • Systematically deleted virulence-associated genes to create multiple isogenic Shigella strains.
  • Characterized engineered strains for attenuation using in vitro and in vivo assays.

    • Main Results:

    • Successfully modified genomic DNA of various bacterial pathogens, including Shigella, using recombineering.
    • Generated multiple isogenic Shigella strains from different serotypes with deletions in virulence genes.
    • Demonstrated attenuation of engineered Shigella strains through comprehensive assays.
    • Developed prototypic Shigella vaccine strains with multiple genetic modifications.

    Conclusions:

    • Recombineering is a powerful tool for efficient genetic manipulation of Shigella.
    • This approach facilitates the creation of well-characterized, attenuated Shigella vaccine candidates.
    • Advanced recombineering holds significant promise for the future of Shigella vaccine development.